Given the updated results of the PREOPANC study, how can gemcitabine-based neoadjuvant chemoradiation be best incorporated into the treatment of resectable or borderline resectable pancreatic cancer?

The PREOPANC-1 trial and the study by Jang et al., PMID 29462005 are currently the only 2 published randomized trials comparing pre-op CRT vs up-front surgery for resectable/borderline resectable PDAC- each of which has now demonstrated an overall survival benefit. The obvious critique is the standa...

The results of PREOPANC, although powerful, is unlikely to change the current common practice of at least a segment of neoadjuvant therapy for PDAC (with CRT component when appropriate based on multidisciplinary discussion).

In addition to the nature of the chemotherapy in both arms, there were 2 mai...